Deutsche Bank set a $23.00 price target on AMAG Pharmaceuticals (NASDAQ:AMAG) in a research report report published on Thursday, September 20th. The brokerage currently has a hold rating on the specialty pharmaceutical company’s stock.
A number of other equities research analysts also recently weighed in on the company. BidaskClub downgraded AMAG Pharmaceuticals from a strong-buy rating to a buy rating in a report on Monday, May 28th. Jefferies Financial Group reaffirmed a hold rating and issued a $22.00 price target on shares of AMAG Pharmaceuticals in a research note on Friday, August 3rd. ValuEngine downgraded AMAG Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Friday, September 14th. B. Riley boosted their price target on AMAG Pharmaceuticals from $30.00 to $31.00 and gave the company a buy rating in a research note on Monday, August 6th. Finally, Cantor Fitzgerald reaffirmed a hold rating and issued a $18.00 price target (up previously from $17.00) on shares of AMAG Pharmaceuticals in a research note on Friday, August 3rd. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. AMAG Pharmaceuticals has a consensus rating of Hold and an average target price of $23.07.
Shares of AMAG traded up $0.85 during midday trading on Thursday, reaching $22.45. 470,936 shares of the stock were exchanged, compared to its average volume of 859,118. AMAG Pharmaceuticals has a twelve month low of $11.93 and a twelve month high of $26.10. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.95 and a current ratio of 2.06. The company has a market capitalization of $689.46 million, a P/E ratio of -3.93 and a beta of 0.56.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its earnings results on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.75) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.54). AMAG Pharmaceuticals had a negative return on equity of 2.77% and a negative net margin of 36.87%. The firm had revenue of $146.25 million for the quarter, compared to analyst estimates of $156.26 million. During the same period in the prior year, the business posted ($0.40) EPS. The firm’s quarterly revenue was up 12.2% compared to the same quarter last year. On average, equities research analysts predict that AMAG Pharmaceuticals will post -3.43 earnings per share for the current fiscal year.
In related news, CEO William K. Heiden sold 5,000 shares of the business’s stock in a transaction dated Tuesday, August 7th. The stock was sold at an average price of $25.00, for a total value of $125,000.00. Following the completion of the transaction, the chief executive officer now owns 328,015 shares of the company’s stock, valued at $8,200,375. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 4.00% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of AMAG. Swiss National Bank raised its stake in AMAG Pharmaceuticals by 13.0% during the first quarter. Swiss National Bank now owns 63,457 shares of the specialty pharmaceutical company’s stock worth $1,279,000 after acquiring an additional 7,300 shares in the last quarter. Northern Trust Corp raised its stake in AMAG Pharmaceuticals by 1.0% during the first quarter. Northern Trust Corp now owns 458,445 shares of the specialty pharmaceutical company’s stock worth $9,237,000 after acquiring an additional 4,468 shares in the last quarter. Employees Retirement System of Texas raised its stake in AMAG Pharmaceuticals by 37.5% during the first quarter. Employees Retirement System of Texas now owns 66,000 shares of the specialty pharmaceutical company’s stock worth $1,330,000 after acquiring an additional 18,000 shares in the last quarter. California Public Employees Retirement System raised its stake in AMAG Pharmaceuticals by 14.4% during the first quarter. California Public Employees Retirement System now owns 96,339 shares of the specialty pharmaceutical company’s stock worth $1,941,000 after acquiring an additional 12,098 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its stake in AMAG Pharmaceuticals by 94.9% during the first quarter. PNC Financial Services Group Inc. now owns 25,652 shares of the specialty pharmaceutical company’s stock worth $518,000 after acquiring an additional 12,491 shares in the last quarter.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
See Also: Stock Symbols and CUSIP Explained
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.